Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ADE regimen

View Patient Information

A regimen consisting of high-dose cytarabine (Ara-C), daunorubicin and etoposide, that is used for the treatment of pediatric and adult acute myeloid leukemia (AML).

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	ADE AraC-daunorubicin-etoposide regimen cytarabine-daunorubicin-etoposide regimen cytarabine/daunorubicin/etoposide high-dose cytarabine-daunorubicin-etoposide regimen high-dose cytarabine/daunorubicin/etoposide high-dose cytarabine/daunorubicin/etoposide regimen MRC AML10 study-ADE regimen
Abbreviation:	ARA-C/DNR/VP-16

ADE regimen

Search NCI's Drug Dictionary